Full article: https://www.ajronline.org/doi/abs/10.2214/AJR.20.24567
Patients with borderline resectable and locally advanced pancreatic cancer receiving neoadjuvant therapy can have results comparable to patients with resectable tumor at presentation, however some patients have early recurrence after neoadjuvant therapy and resection. Jordan Perchik, MD discusses a new AJR study in which a team of radiologists evaluate multiple imaging parameters and tumor metrics to assess for characteristics to predict pathologic response prior to resection.
View all episodes
By AJR
4.5
4343 ratings
Full article: https://www.ajronline.org/doi/abs/10.2214/AJR.20.24567
Patients with borderline resectable and locally advanced pancreatic cancer receiving neoadjuvant therapy can have results comparable to patients with resectable tumor at presentation, however some patients have early recurrence after neoadjuvant therapy and resection. Jordan Perchik, MD discusses a new AJR study in which a team of radiologists evaluate multiple imaging parameters and tumor metrics to assess for characteristics to predict pathologic response prior to resection.
16,477 Listeners
86 Listeners
27 Listeners
315 Listeners
26,416 Listeners
74 Listeners
27 Listeners
7,713 Listeners
6,644 Listeners
5,116 Listeners
200 Listeners
5,351 Listeners
15,337 Listeners
39 Listeners
421 Listeners